MSD
MSD’s Alzheimer’s study could break new ground for treatment
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, MSD, clinical trials
MSD, known as Merck in North America, has published results of a Phase I trial of verubecestat. The drug is …
MSD’s Keytruda given first FDA approval for first line treatment
October 25, 2016Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo
MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …
MSD’s Keytruda early success ends trial early
October 24, 2016Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq
MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
MSD’s antiviral drug hits endpoint targets in Phase III trials
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AiCuris, MSD, Merck, bone marrow, letermovir, transplant
MSD, known as Merck in the US, released news of the successful meeting of its primary endpoints in its Phase …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
MSD’s Keytruda twice as successful against standard therapy for lung cancer
October 10, 2016Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda
MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …
Merck’s Keytruda suffers rejection at hands of NICE
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda
NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
Sanofi accuses MSD of US patent infringement
September 19, 2016Sales and Marketing MSD, Sanofi, lawsuit
Sanofi has filed a suit against MSD in the United States District Court for the District of Delaware accusing the …
FDA to review MSD’s Keytruda as a first-line lung cancer treatment
September 7, 2016Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo
The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …
MSD drops osteoporosis trial drug due to stroke risk
September 5, 2016Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke
MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
MSD to cut 148 jobs at Pennsylvania plant
August 16, 2016Manufacturing and Production, Research and Development MSD, job cuts, zontivity
MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s …
FDA approves MSD’s Keytruda for head and neck cancer treatment
August 8, 2016Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …
MSD files Lantus biosimilar with FDA
August 8, 2016Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar
MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …
Takeover rumours send Biogen’s stock soaring
August 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover
Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
